ES2593360T3 - Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica - Google Patents

Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica Download PDF

Info

Publication number
ES2593360T3
ES2593360T3 ES10182298.9T ES10182298T ES2593360T3 ES 2593360 T3 ES2593360 T3 ES 2593360T3 ES 10182298 T ES10182298 T ES 10182298T ES 2593360 T3 ES2593360 T3 ES 2593360T3
Authority
ES
Spain
Prior art keywords
acid sequence
seq
amino acid
protein
mature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10182298.9T
Other languages
English (en)
Spanish (es)
Inventor
Gary W. Zlotnick
Leah D. Fletcher
John Farley
Liesel A. Bernfield
Robert J Zagursky
Benjamin J. Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2593360(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Application granted granted Critical
Publication of ES2593360T3 publication Critical patent/ES2593360T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
ES10182298.9T 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica Expired - Lifetime ES2593360T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US328101P 2001-10-11
US40693402P 2002-08-30 2002-08-30
US406934P 2002-08-30

Publications (1)

Publication Number Publication Date
ES2593360T3 true ES2593360T3 (es) 2016-12-07

Family

ID=27668840

Family Applications (14)

Application Number Title Priority Date Filing Date
ES10182298.9T Expired - Lifetime ES2593360T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182469.6T Expired - Lifetime ES2625876T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182324.3T Expired - Lifetime ES2549764T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES02804818.9T Expired - Lifetime ES2568895T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182437.3T Expired - Lifetime ES2532639T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182590.9T Expired - Lifetime ES2561430T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182487.8T Expired - Lifetime ES2615206T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10183020.6T Expired - Lifetime ES2532640T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182544.6T Expired - Lifetime ES2603532T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182364.9T Expired - Lifetime ES2609039T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182611.3T Expired - Lifetime ES2562811T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182399.5T Expired - Lifetime ES2603531T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182345.8T Expired - Lifetime ES2549765T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES17156888T Expired - Lifetime ES2781213T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Family Applications After (13)

Application Number Title Priority Date Filing Date
ES10182469.6T Expired - Lifetime ES2625876T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182324.3T Expired - Lifetime ES2549764T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES02804818.9T Expired - Lifetime ES2568895T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182437.3T Expired - Lifetime ES2532639T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182590.9T Expired - Lifetime ES2561430T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182487.8T Expired - Lifetime ES2615206T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10183020.6T Expired - Lifetime ES2532640T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182544.6T Expired - Lifetime ES2603532T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182364.9T Expired - Lifetime ES2609039T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182611.3T Expired - Lifetime ES2562811T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182399.5T Expired - Lifetime ES2603531T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182345.8T Expired - Lifetime ES2549765T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES17156888T Expired - Lifetime ES2781213T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Country Status (18)

Country Link
US (13) US8101194B2 (OSRAM)
EP (14) EP2341063B1 (OSRAM)
JP (6) JP2005515771A (OSRAM)
KR (4) KR101068318B1 (OSRAM)
CN (4) CN105617372A (OSRAM)
AU (3) AU2009213040C1 (OSRAM)
BE (3) BE2017C056I2 (OSRAM)
BR (1) BRPI0212999B8 (OSRAM)
CA (5) CA2463476C (OSRAM)
DK (10) DK2343308T3 (OSRAM)
ES (14) ES2593360T3 (OSRAM)
FR (4) FR15C0056I2 (OSRAM)
IL (5) IL161052A0 (OSRAM)
LU (4) LU92786I2 (OSRAM)
MX (3) MX339524B (OSRAM)
NL (4) NL300755I2 (OSRAM)
PT (10) PT2351767E (OSRAM)
WO (1) WO2003063766A2 (OSRAM)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093517B1 (en) 1998-05-01 2008-03-05 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
WO2001064922A2 (en) 2000-02-28 2001-09-07 Chiron Spa Heterologous expression of neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
BR122017002991B1 (pt) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
EP3311836A1 (en) 2005-04-08 2018-04-25 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008013943A2 (en) 2006-07-27 2008-01-31 Wyeth High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
AU2010227220B2 (en) * 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
CN102834410B (zh) * 2010-03-30 2016-10-05 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
PT2575870T (pt) 2010-06-04 2017-02-10 Wyeth Llc Formulações de vacinas
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
SI2608805T2 (sl) * 2010-08-23 2025-09-30 Wyeth Llc Stabilne formulacije antigenov rLP2086 neisserie meningitidis
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
RU2013144207A (ru) 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
CA2862247A1 (en) * 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
JP2015517089A (ja) 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
US10376573B2 (en) * 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CN105431167A (zh) 2013-08-02 2016-03-23 奥克兰儿童医院及研究中心 非天然发生因子h结合蛋白(fhbp)及其使用方法
KR20210002757A (ko) * 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CN119613509A (zh) 2014-07-23 2025-03-14 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
FI3506935T3 (fi) 2016-09-02 2024-04-17 Sanofi Pasteur Inc Neisseria meningitidis -rokote
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN111133378B (zh) 2017-09-28 2021-04-23 富士胶片株式会社 摄像装置、信息获取方法及记录介质
WO2019065554A1 (ja) * 2017-09-28 2019-04-04 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN114681601B (zh) * 2020-12-31 2025-08-19 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
CN118613207A (zh) 2022-01-24 2024-09-06 皇家飞利浦有限公司 使用血管内数据与管腔外图像之间的共配准的脉搏波速度确定以及相关联的系统、设备和方法
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用
CN120241991A (zh) * 2025-06-05 2025-07-04 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0432216A1 (en) 1988-09-01 1991-06-19 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
KR100188323B1 (ko) * 1989-03-09 1999-06-01 이곤 이이 버어그 비타입성 헤모필루스 인플렌자에 대한 백신
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
JPH0453645U (OSRAM) * 1990-09-12 1992-05-07
CA2091678C (en) 1990-09-25 2003-04-22 Stephen C. Inglis Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993007897A1 (en) 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
WO1994021807A2 (en) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
PL179877B1 (pl) 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1995007358A1 (en) 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
WO1995029662A2 (en) * 1994-04-20 1995-11-09 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
WO1996039036A1 (en) 1995-06-05 1996-12-12 The University Of Alabama At Birmingham Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
ATE339436T1 (de) * 1995-06-07 2006-10-15 Sanofi Pasteur Inc Expression von lipoproteinen
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
ATE252602T1 (de) 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
WO1999001158A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
BR9810500A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Sistema e aparelho para a transferência de ácido nucléico in vivo para o interior de células de organismos eucarióticos pluricelulares
AU8444698A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into multicelled eukaryo tic organism cells and combination therefor
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Ｂ型髄膜炎菌性ポーリンおよびＨ．ｉｎｆｌｕｅｎｚａｅ多糖体を含む免疫原性結合体
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
JP2001514269A (ja) * 1997-08-29 2001-09-11 ザ ダウ ケミカル カンパニー 均質な、充填剤含有高分子複合体
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1047784B2 (en) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
BR9909097A (pt) * 1998-02-03 2000-12-05 Ct Disease Contr & Prevention Molécula hìbrida de ácido nucleico, vetor de expressão, processos para preparação e para a produção de proteìna psaa lipidada recombinante, proteìna psaa lipidada isolada e purificada produzida recombinantemente, composição imunológica, processos para induzir uma resposta imunológica em um animal e para imunizar um hospedeiro contra infecção pneumocócica, e, composição imunogênica para administração intranasal a um hospedeiro
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1093517B1 (en) * 1998-05-01 2008-03-05 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
PT1741443E (pt) 1998-05-29 2014-07-31 Novartis Vaccines & Diagnostic Combinação de vacinas para a meningite b/c
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
DE69919754T2 (de) 1998-09-30 2005-09-01 Walter Reed Army Institute Of Research Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
EP1144998A3 (en) 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
AU2289000A (en) 1999-01-15 2000-08-01 Smithkline Beecham Biologicals (Sa) (neisseria meningitidis) polypeptide basb052
CA2360658A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
DE60040727D1 (de) 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
ATE279943T1 (de) 1999-02-26 2004-11-15 Chiron Srl Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
DE60042114D1 (de) 1999-04-30 2009-06-10 Craig J Venter Inst Inc Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
NZ545647A (en) * 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2390344C (en) 1999-11-29 2014-08-26 Chiron Spa 85kda neisserial antigen
ATE400296T1 (de) 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
WO2001064922A2 (en) * 2000-02-28 2001-09-07 Chiron Spa Heterologous expression of neisserial proteins
DK1296713T3 (da) 2000-06-08 2004-01-26 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunstimulerende oligodeoxynukleotider
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
EP1373314A2 (en) 2001-03-30 2004-01-02 Geneprot, Inc. Human arginine-rich protein-related compositions
US6942802B2 (en) 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
ATE455793T1 (de) 2001-04-17 2010-02-15 Novartis Vaccines & Diagnostic Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2460546A1 (en) 2001-09-14 2003-03-27 Invitrogen Corporation Dna polymerases and mutants thereof
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ATE419278T1 (de) 2002-03-26 2009-01-15 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011248A (es) 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
KR20060019515A (ko) 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
DE602004022286D1 (de) 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BR122017002991B1 (pt) 2003-10-02 2023-01-10 Novartis Vaccines And Diagnostics S.R.L. Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
JP2007517057A (ja) 2003-12-30 2007-06-28 ワイス 改善された耐容性を有する免疫原性組成物中の疎水性タンパク質の処方物
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CN101014618B (zh) 2004-07-23 2013-01-02 诺华疫苗和诊断有限公司 抗原的寡聚装配多肽
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP1855715B1 (en) * 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
CA2600113A1 (en) 2005-03-07 2006-09-14 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biological S North America Pharmaceutical liposomal compositions
PL1885734T3 (pl) 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
MX348734B (es) 2005-09-01 2017-06-27 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vacunacion multiple que incluye meningococcus del serogrupo c.
EP2333549A3 (en) 2005-09-05 2011-11-02 GlaxoSmithKline Biologicals s.a. Serum bactericidal assay for n. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007071786A2 (en) 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
WO2007111940A2 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
ATE450271T1 (de) 2006-06-12 2009-12-15 Glaxosmithkline Biolog Sa Impfstoff
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
WO2008013943A2 (en) 2006-07-27 2008-01-31 Wyeth High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101678094B (zh) 2007-06-04 2014-08-27 诺华股份有限公司 脑膜炎疫苗制剂
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20090035328A1 (en) 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2009143168A2 (en) 2008-05-19 2009-11-26 Novartis Ag Vaccine assays
WO2009158142A1 (en) 2008-05-30 2009-12-30 The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
MX374128B (es) 2008-10-29 2025-03-05 Ablynx Nv Formulaciones de moléculas de unión a antígeno de dominio sencillo.
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
AU2010242905B2 (en) 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544712A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
CN102834410B (zh) 2010-03-30 2016-10-05 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
SI2608805T2 (sl) 2010-08-23 2025-09-30 Wyeth Llc Stabilne formulacije antigenov rLP2086 neisserie meningitidis
ES2744471T3 (es) 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
RU2013144207A (ru) 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
ES2549765T3 (es) 2015-11-02
US20150216960A1 (en) 2015-08-06
US20120201844A1 (en) 2012-08-09
NL300897I2 (nl) 2018-04-06
FR17C1042I1 (OSRAM) 2017-12-22
JP5923070B2 (ja) 2016-05-24
CN102836426A (zh) 2012-12-26
AU2012202916B2 (en) 2013-08-01
HK1178429A1 (zh) 2013-09-13
US20170173140A1 (en) 2017-06-22
BE2017C057I2 (OSRAM) 2022-02-01
ES2609039T3 (es) 2017-04-18
EP2341063A2 (en) 2011-07-06
FR17C1044I2 (fr) 2018-12-07
EP1442047B1 (en) 2016-03-16
AU2009213040C1 (en) 2012-10-11
CA2894296C (en) 2018-05-01
EP2341062A3 (en) 2011-09-14
US20120308595A1 (en) 2012-12-06
EP2341063B1 (en) 2015-08-26
BRPI0212999B1 (pt) 2020-04-28
NL300896I2 (nl) 2018-04-06
FR17C1043I1 (OSRAM) 2017-12-22
NL300896I1 (nl) 2017-10-20
DK3199539T3 (da) 2020-04-27
NL300899I1 (nl) 2017-10-20
IL161052A0 (en) 2004-08-31
EP2348035A3 (en) 2011-09-14
CN1578785A (zh) 2005-02-09
US20190151431A1 (en) 2019-05-23
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
US9107873B2 (en) 2015-08-18
LUC00041I1 (OSRAM) 2017-10-16
NL300897I1 (nl) 2017-10-20
WO2003063766A3 (en) 2004-01-08
US8563007B1 (en) 2013-10-22
US8101194B2 (en) 2012-01-24
EP2341062B1 (en) 2017-03-29
CA2849427C (en) 2016-10-04
KR20110117726A (ko) 2011-10-27
ES2615206T3 (es) 2017-06-05
US9623101B2 (en) 2017-04-18
FR17C1043I2 (fr) 2018-12-07
JP5404441B2 (ja) 2014-01-29
AU2009213040A1 (en) 2009-10-08
DK2341062T3 (en) 2017-05-08
CA2463476C (en) 2017-09-12
EP2348035B1 (en) 2015-02-18
ES2781213T3 (es) 2020-08-31
JP2014012002A (ja) 2014-01-23
FR17C1044I1 (OSRAM) 2017-12-22
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
JP2016165275A (ja) 2016-09-15
EP2371837A1 (en) 2011-10-05
US20120301496A1 (en) 2012-11-29
PT2351767E (pt) 2015-10-30
EP1442047A4 (en) 2005-06-01
EP2366707B1 (en) 2016-09-21
EP2371838B1 (en) 2015-12-16
EP2366707A1 (en) 2011-09-21
EP2348036A3 (en) 2011-08-03
LU92786I2 (fr) 2015-11-02
EP2332961A2 (en) 2011-06-15
ES2603531T3 (es) 2017-02-28
PT2343308E (pt) 2015-03-25
US11116829B2 (en) 2021-09-14
MX349481B (es) 2017-07-31
ES2532639T3 (es) 2015-03-30
EP2371836B1 (en) 2016-12-14
CN105617372A (zh) 2016-06-01
EP3199539B1 (en) 2020-03-11
EP2351767A3 (en) 2011-09-14
IL245956B (en) 2019-02-28
FR17C1042I2 (fr) 2018-12-07
DK2343308T3 (en) 2015-03-30
CA2918207A1 (en) 2003-08-07
AU2009213040B2 (en) 2012-03-01
BRPI0212999B8 (pt) 2021-07-27
FR15C0056I1 (OSRAM) 2015-09-11
IL233545A (en) 2017-10-31
ES2568895T3 (es) 2016-05-05
EP2343308B1 (en) 2015-02-18
EP1442047A2 (en) 2004-08-04
US20130259889A1 (en) 2013-10-03
PT2371836T (pt) 2017-02-17
LUC00042I1 (OSRAM) 2017-10-16
EP2348036B1 (en) 2015-12-16
IL245956A0 (en) 2016-07-31
EP2332961B1 (en) 2016-07-27
DK2341063T3 (en) 2015-10-26
KR20040066793A (ko) 2004-07-27
US9757444B2 (en) 2017-09-12
WO2003063766A2 (en) 2003-08-07
KR101099916B1 (ko) 2011-12-28
EP2332961A3 (en) 2011-07-27
KR20100028657A (ko) 2010-03-12
EP2348036A2 (en) 2011-07-27
CA2939781A1 (en) 2003-08-07
ES2561430T3 (es) 2016-02-26
CA2918207C (en) 2016-10-18
MXPA04003356A (es) 2004-11-29
JP5976880B2 (ja) 2016-08-24
US9168293B2 (en) 2015-10-27
CA2849427A1 (en) 2003-08-07
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
EP2341062A2 (en) 2011-07-06
CN1578785B (zh) 2013-03-13
EP2348034A2 (en) 2011-07-27
NL300899I2 (nl) 2018-04-06
DK2351767T3 (en) 2015-10-26
IL245955B (en) 2018-01-31
PT2332961T (pt) 2016-09-28
US8563006B2 (en) 2013-10-22
MX339524B (es) 2016-05-30
AU2012202916C1 (en) 2017-06-08
JP2010162023A (ja) 2010-07-29
DK2348035T3 (en) 2015-04-20
DK2332961T3 (en) 2016-10-03
CA2894296A1 (en) 2003-08-07
PT2371838E (pt) 2016-03-23
EP2371837B1 (en) 2016-09-21
JP2005515771A (ja) 2005-06-02
CN102836426B (zh) 2016-09-28
BE2017C055I2 (OSRAM) 2022-02-01
JP5997400B2 (ja) 2016-09-28
DK2348036T3 (en) 2016-02-22
EP2343308A2 (en) 2011-07-13
DK2371836T3 (en) 2017-02-20
EP2343308A3 (en) 2011-07-27
IL245955A0 (en) 2016-07-31
FR15C0056I2 (fr) 2016-06-03
ES2603532T3 (es) 2017-02-28
EP2371838A1 (en) 2011-10-05
ES2532640T3 (es) 2015-03-30
KR20100121699A (ko) 2010-11-18
PT3199539T (pt) 2020-04-01
CN102755631B (zh) 2015-11-25
CA2463476A1 (en) 2003-08-07
HK1178800A1 (zh) 2013-09-19
ES2549764T3 (es) 2015-11-02
LUC00040I2 (OSRAM) 2017-12-20
US20120034261A1 (en) 2012-02-09
LUC00042I2 (OSRAM) 2017-12-20
BE2017C056I2 (OSRAM) 2022-02-01
PT2348035E (pt) 2015-03-25
JP2017025061A (ja) 2017-02-02
AU2012202916A1 (en) 2012-06-07
CN102755631A (zh) 2012-10-31
EP2351767B1 (en) 2015-08-26
BR0212999A (pt) 2006-05-23
US20120294880A1 (en) 2012-11-22
LUC00041I2 (OSRAM) 2017-12-20
US20060257413A1 (en) 2006-11-16
PT2341063E (pt) 2015-10-29
NL300755I2 (nl) 2025-11-25
EP2371836A1 (en) 2011-10-05
AU2018203627A1 (en) 2018-06-07
PT2348036E (pt) 2016-03-09
EP2348034A3 (en) 2011-09-21
IL233545A0 (en) 2014-08-31
LUC00040I1 (OSRAM) 2017-10-16
US10300122B2 (en) 2019-05-28
CA2939781C (en) 2022-09-13
IL161052A (en) 2015-04-30
ES2562811T3 (es) 2016-03-08
US9132182B2 (en) 2015-09-15
DK2371838T3 (en) 2016-02-22
ES2625876T3 (es) 2017-07-20
EP2348034B1 (en) 2016-11-02
EP2351767A2 (en) 2011-08-03
EP2341063A3 (en) 2011-09-14
EP3199539A1 (en) 2017-08-02
EP2348035A2 (en) 2011-07-27
JP2015214545A (ja) 2015-12-03

Similar Documents

Publication Publication Date Title
ES2593360T3 (es) Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
EP1300156A2 (en) Otitis media vaccine
JP2006525330A (ja) 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
TW200844226A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
JPH09500538A (ja) ナイセリア・メニンギチジス外膜グループｂポーリンタンパク質の高レベル発現、精製および再生
Zhang et al. Two CheW coupling proteins are essential in a chemosensory pathway of Borrelia burgdorferi
Cullen et al. Construction and evaluation of a plasmid vector for the expression of recombinant lipoproteins in Escherichia coli
JP2011057679A (ja) ナイセリアＮｓｐＡタンパク質をリフォールディングする方法
EP2391640B1 (en) A clostridium chauvoei polypeptide, dna encoding the polypeptide and a vaccine comprising the polypeptide
ES2351598T3 (es) Proteína frpb mutante y procedimiento de replegamiento.
KR0158435B1 (ko) 헬리코박터 파이로리의 외막단백질 유전자 및 그를 발현하는 재조합 미생물
Raghunathan et al. Human Factor H and anti-Neisserial surface protein A (NspA) antibodies compete for overlapping binding sites on meningococcal NspA
JP2005027652A (ja) レプトスピラタンパク質、これをコードする遺伝子、レプトスピラ病に対する感染防御活性を有する薬剤、及び診断キット
HK1178800B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease